Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.77 |
| ▸ | DRD1 | P21728 | 2/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
| ▸ | HTR2B | P41595 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.77 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CES1 | P23141 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403893 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL30277249 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL3173500 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL364610 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL4770 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL19148650 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Water SCHEMBL3377943 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6635560 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL1130039 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Iodide SCHEMBL1402210 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011018784-A1 | PACKAGE FOR ALTERNATING MEDICATIONS | MOHR REPHAEL (IL) | 2011-02-17 | — | — | WO | claimed |
| EP-3397139-B1 | DEVICE, SYSTEM AND METHOD FOR NON-INVASIVE MONITORING OF PHYSIOLOGICAL MEASUREMENTS | WEAR2B LTD (IL) | 2024-01-31 | — | — | EP | disclosed |
| CN-108601529-B | Apparatus, system and method for non-invasive monitoring of physiological measurements | 威尔图比有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11129556-B2 | Device, system and method for non-invasive monitoring of physiological measurements | Wear2B Ltd. (IL) | 2021-09-28 | — | — | US | disclosed |
| US-20190008432-A1 | DEVICE, SYSTEM AND METHOD FOR NON-INVASIVE MONITORING OF PHYSIOLOGICAL MEASUREMENTS | Wear2B Ltd. (IL) | 2019-01-10 | — | — | US | disclosed |
| EP-3397139-A1 | DEVICE, SYSTEM AND METHOD FOR NON-INVASIVE MONITORING OF PHYSIOLOGICAL MEASUREMENTS | Wear2b Ltd (IL) | 2018-11-07 | — | — | EP | disclosed |
| CN-108601529-A | The equipment, system and method for non-invasive monitoring for physiological measurements | 威尔图比有限公司 | 2018-09-28 | — | — | CN | disclosed |
| WO-2017115361-A1 | DEVICE, SYSTEM AND METHOD FOR NON-INVASIVE MONITORING OF PHYSIOLOGICAL MEASUREMENTS | WEAR2B LTD (IL) | 2017-07-06 | — | — | WO | disclosed |
| US-9029390-B2 | Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base | CLL PHARMA (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20090264460-A1 | CLOPIDOGREL PHARMACEUTICAL FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-10-22 | — | — | US | disclosed |
| EP-1768660-A4 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | ATHEROGENICS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1768660-A2 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | Atherogenics, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1758664-A2 | PROCESS EMPLOYING CONTROLLED CRYSTALLIZATION IN FORMING CRYSTALS OF A PHARMACEUTICAL | Bristol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006007508-A2 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | ATHEROGENICS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005108380-A2 | PROCESS EMPLOYING CONTROLLED CRYSTALLIZATION IN FORMING CRYSTALS OF A PHARMACEUTICAL | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | ABCB11 3655/4885OPRM1 4275/4885CYP2C19 4641/4885 |
| US-20090264460-A1 | CLOPIDOGREL PHARMACEUTICAL FORMULATIONS | PFKP, P2RY11, P2RY12 | ABCB11 150/4885OPRM1 2982/4885CYP2C19 8/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | ABCB11 726/4885OPRM1 1074/4885CYP2C19 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.